Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS627 vs Pertuzumab with trastuzumab + docetaxel as neoadjuvant therapy in HER2-positive breast cancer
CTR20200737Phase 3Completed
- Sponsor
- Mabworks Biotech
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of hs627 in breast cancer, sponsored by Mabworks Biotech. Started Jul 2020; status: completed.
02
Drugs
hs627
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200737.